Best-in-class
anticancer
drug

HLB develops the ‘Rivoceranib’, the Best-in-class
targeted therapy for unmet medical needs in cancer.

Leader of Global
Pharma

HLB navigates the way to the future by developing
First-in-class drugs with continuous innovation and challenges.

Notice

IR Letter

News